enow.com Web Search

  1. Ads

    related to: bicalutamide and lupron prostate cancer

Search results

  1. Results from the WOW.Com Content Network
  2. Bicalutamide - Wikipedia

    en.wikipedia.org/wiki/Bicalutamide

    Bicalutamide, sold under the brand name Casodex among others, is an antiandrogen medication that is primarily used to treat prostate cancer. [10] It is typically used together with a gonadotropin-releasing hormone (GnRH) analogue or surgical removal of the testicles to treat metastatic prostate cancer (mPC).

  3. Comparison of bicalutamide with other antiandrogens

    en.wikipedia.org/wiki/Comparison_of_bicalutamide...

    Bicalutamide also shows a better safety profile than cyproterone acetate. When used as a high-dosage monotherapy, bicalutamide shows slightly inferior effectiveness in the treatment of prostate cancer compared to castration and GnRH analogues but a different and potentially superior tolerability and safety profile.

  4. Side effects of bicalutamide - Wikipedia

    en.wikipedia.org/wiki/Side_effects_of_bicalutamide

    [45] [46] Moreover, the lifetime incidence of breast cancer in men is approximately 0.1%, [47] the average age of diagnosis of prostate cancer and male breast cancer are similar (around 70 years), [10] [48] and millions of men have been treated with bicalutamide for prostate cancer, [49] all of which are potentially in support of the notion of ...

  5. Medical uses of bicalutamide - Wikipedia

    en.wikipedia.org/wiki/Medical_uses_of_bicalutamide

    Bicalutamide is used primarily in the treatment of early and advanced prostate cancer. [1] It is approved at a dosage of 50 mg/day as a combination therapy with a gonadotropin-releasing hormone analogue (GnRH analogue) or orchiectomy (that is, surgical or medical castration) in the treatment of stage D2 metastatic prostate cancer (mPC), [2] [3] and as a monotherapy at a dosage of 150 mg/day ...

  6. Leuprorelin - Wikipedia

    en.wikipedia.org/wiki/Leuprorelin

    Lupron injection was approved by the FDA for treatment of advanced prostate cancer on 9 April 1985. [45] [4] [43] [44] Lupron depot for monthly intramuscular injection was approved by the FDA for palliative treatment of advanced prostate cancer on 26 January 1989. [8]

  7. Flutamide - Wikipedia

    en.wikipedia.org/wiki/Flutamide

    In accordance, 50 mg/day bicalutamide has been found to possess equivalent or superior effectiveness to 750 mg/day flutamide in a large clinical trial for prostate cancer. [112] Also, bicalutamide has been shown to be 5-fold more potent than flutamide in rats and 50-fold more potent than flutamide in dogs. [112]

  1. Ads

    related to: bicalutamide and lupron prostate cancer